Relevant studies have shown that SGLT-2 inhibitors can not only reduce blood glucose, but also improve endothelial dysfunction, improve ventricular loading conditions, improve cardiac metabolism and bioenergetics, inhibit cardiac fibrosis, inhibit adipocytokines, reduce blood pressure and have direct effects on Na+/H+ exchange in the myocardium, so as to have a protective effect against cardiovascular disease (8, 9). Here, SLC5A2 is linked to cardiovascular disorder.